MDxHealth Inks Marketing Deal with LI Path for Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a co-marketing agreement with Long Island Pathology to promote MDxHealth's ConfirmMDx for Prostate Cancer test.

LI Path is an independent anatomic and clinical pathology lab serving the New York City metropolitan area, and MDxHealth expects the deal to expand its access to urologists in that market. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.